These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 2857928

  • 1. Butazones under fire.
    Herxheimer A, Collier J, Rawlins MD, Schönhöfer P, Medawar C, Melrose D, Bannenberg W, Beardshaw V.
    Lancet; 1985 Mar 09; 1(8428):580. PubMed ID: 2857928
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Withdrawal of oxyphenbutazone: what about phenylbutazone?
    Biron P.
    CMAJ; 1986 May 15; 134(10):1119-20. PubMed ID: 3697857
    [No Abstract] [Full Text] [Related]

  • 4. Phenylbutazone, oxyphenbutazone labeling revised.
    FDA Drug Bull; 1984 Dec 15; 14(3):23-4. PubMed ID: 6526172
    [No Abstract] [Full Text] [Related]

  • 5. Fixed drug eruption to oxyphenbutazone and phenylbutazone.
    Nayyar KC, Pasricha JS.
    Dermatologica; 1972 Dec 15; 144(4):214-6. PubMed ID: 5076722
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phenylbutazone and oxyphenbutazone: time to call a halt.
    Drug Ther Bull; 1984 Jan 27; 22(2):5-6. PubMed ID: 6692755
    [No Abstract] [Full Text] [Related]

  • 9. Contact sensitivity to oxyphenbutazone (Tanderil) and cross-sensitivity to phenylbutazone (Butazolidine).
    Krook G.
    Contact Dermatitis; 1975 Dec 27; 1(6):385-6. PubMed ID: 139265
    [No Abstract] [Full Text] [Related]

  • 10. Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone.
    Inman WH.
    Br Med J; 1977 Jun 11; 1(6075):1500-5. PubMed ID: 871632
    [Abstract] [Full Text] [Related]

  • 11. Contact sensitivity to oxyphenbutazone (Tanderil) and cross-sensitivity to phenylbutazone (Butazolidin).
    Krook G.
    Contact Dermatitis; 1975 Aug 11; 1(4):262. PubMed ID: 139243
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Therapeutic hazards of phenylbutazone and oxyphenbutazone in polymyalgia rheumatica.
    Wadman B, Werner I.
    Lancet; 1967 Mar 18; 1(7490):597-8. PubMed ID: 4163976
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Clofezone and oxyphenbutazone excluded from dental use].
    Tamura T.
    Nihon Shika Ishikai Zasshi; 1984 Mar 18; 37(4):391-5. PubMed ID: 6241218
    [No Abstract] [Full Text] [Related]

  • 16. Adverse reactions with long-term use of phenylbutazone and oxyphenbutazone.
    Sperling IL.
    Lancet; 1969 Sep 06; 2(7619):535-7. PubMed ID: 4184850
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Ketazon not more gentle to the stomach than Blutazolidin].
    Kuschinsky G.
    Med Klin; 1972 May 12; 67(19):686. PubMed ID: 5054952
    [No Abstract] [Full Text] [Related]

  • 20. Contact sensitivity to oxyphenbutazone.
    Valsecchi R, Serra M, Foiadelli L, Cainelli T.
    Contact Dermatitis; 1981 May 12; 7(3):157. PubMed ID: 7273732
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.